Fremanezumab-vfrm

(Ajovy®)

Fremanezumab-vfrm

Drug updated on 9/5/2024

Dosage FormInjection (subcutaneous; 225 mg/1.5 mL)
Drug ClassCalcitonin gene-related peptide receptor antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the preventive treatment of migraine in adults.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Ajovy (fremanezumab-vfrm) is indicated for the preventive treatment of migraine in adults.
  • This summary is based on the review of 28 systematic review(s)/meta-analysis(es). [1-28]
  • Fremanezumab significantly reduced monthly migraine days compared to placebo, with the most effective dose for chronic migraine showing a mean difference of -2.77 days (95% CrI: -3.36 to -2.17).
  • The responder rate for patients achieving at least a 50% reduction in mean monthly migraine days was 54%, with a similar rate (57%) for mean monthly headache days.
  • Fremanezumab was effective in transitioning patients from medication overuse status, particularly in the triptan group, with a relative risk (RR) of 1.71 (95% CI: 1.53 to 1.91; p < 0.001).
  • In comparisons with other treatments, fremanezumab often showed superior effectiveness in reducing monthly migraine days, especially when compared to topiramate and onabotulinumtoxinA, with a higher likelihood of benefit versus harm.
  • The majority of study participants were women (85.1%), with only two studies analyzing results by sex and no specific discussion of results for men. Effectiveness was observed in both episodic and chronic migraine patients, with slightly better outcomes in chronic migraine. Fremanezumab was notably effective in reducing medication overuse, particularly in patients with medication overuse or medication overuse headache, with a higher responder rate in the triptan group.

Product Monograph / Prescribing Information

Document TitleYearSource
Ajovy (fremanezumab-vfrm) Prescribing Information.2022Teva Pharmaceuticals USA, North Wales, PA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Reporting quality and risk of bias analysis of published RCTs assessing anti-CGRP monoclonal antibodies in Migraine Prophylaxis: a systematic review.2024Journal of Clinical Medicine
The transition of medication overuse status by acute medication categories in episodic or chronic migraine patients to non-overuse status after receiving anti-CGRP monoclonal antibodies: a systematic review and meta-analysis of phase 3 randomized control trial.2024Neurological Sciences
Clinical effectiveness of pharmacological interventions for managing chronic migraine in adults: a systematic review and network meta-analysis.2023The Journal of Headache and Pain
Effectiveness of calcitonin gene-related peptide monoclonal antibodies in the prevention of migraine: a systematic review and meta-analysis of observational cohort studies. 2023Clinical Drug Investigation
Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis.2023Cephalalgia
Effectiveness and safety of chronic migraine preventive treatments: a systematic literature review.2023Pain and Therapy
Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials.2023Cephalalgia
Gender bias in clinical trials of biological agents for migraine: a systematic review.2023PLoS One
Comparative efficacy and safety of five anti-calcitonin gene-related peptide agents for migraine prevention: a network meta-analysis.2023Clinical Journal of Pain
Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review. 2023The Journal of Headache and Pain
Comparative effectiveness and tolerability of the pharmacology of monoclonal antibodies targeting the calcitonin gene-related peptide and its receptor for the prevention of chronic migraine: a network meta analysis of randomized controlled trials.2022Neurotherapeutics
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review.2022European Journal of Medical Research
A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine.2022The Journal of Headache and Pain
Monoclonal antibodies against calcitonin gene-related peptide for migraine prophylaxis: a systematic review of real-world data.2022Cells
Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials. 2021Naunyn-Schmiedeberg's Archives of Pharmacology
Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): a network meta-analysis of randomized controlled trials. 2021Journal of the Neurological Sciences
Calcitonin gene-related peptide monoclonal antibodies versus botulinum neurotoxin A in the preventive treatment of chronic migraine: an adjusted indirect treatment comparison meta-analysis. 2021Frontiers in Pharmacology
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine: a systematic review and network meta-analysis. 2021Frontiers in Pharmacology
Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis. 2021Cephalalgia
Calcitonin gene–related peptide monoclonal antibody versus botulinum toxin for the preventive treatment of chronic migraine: evidence from indirect treatment comparison. 2021Frontiers in Pharmacology
Indirect comparison of topiramate and monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: a systematic review with meta-analysis.2021CNS Drugs
Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: a systematic review and network meta-analysis.2021Clinical Neurology and Neurosurgery
Quality of life related to functional disability in migraine patients: a systematic review and network meta-analysis.2021The Clinical Journal of Pain
Safety and efficacy of fremanezumab for the prevention of migraine: a meta-analysis from randomized controlled trials.2020Frontiers in Neurology
Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis.2020BMC Neurology
Optimal treatment strategy of fremanezumab in migraine prevention: a systematic review with network meta‑analysis of randomized clinical trials. 2020Scientific Reports
Monoclonal antibodies against calcitonin gene-related peptide in chronic migraine: an adjusted indirect treatment comparison. 2020Farmacia Hospitalaria
CGRP, a target for preventive therapy in migraine and cluster headache: systematic review of clinical data. 2019Cephalalgia

Clinical Practice Guidelines